Business
Lifeline's Affiliate, Cyrcadia Commences Clinical Trial
Lifeline's Affiliate, Cyrcadia Commences Clinical Trial.
About this update from Lifeline Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n Lifeline's Affiliate, Cyrcadia Commences Clinical Trial\n \n \nLifeline's Affiliate, Cyrcadia Commences Clinical Trial\n \n RENO, NV--(Marketwired - Jul 7, 2015) - Lifeline (OTC PINK: LLBO) and Cyrcadia, Inc. (\"Cyrcadia\") announce that Cyrcadia has commenced a clinical trial for its wearable early detection of breast cancer device and is enrolling the first trial participants at El Camino Hospital, in Mountain View, California. Utilizing its previous FDA cleared device as a predicate, Cyrcadia is combining its fourth generation, wearable device technology, made by Flextronics, and the Salesforce database software to track the clinical trial results.\n About El Camino Hospital\n El Camino Hospital is an acute-care, 443-bed, nonprofit and locally governed organization with campuses in Mountain View and Los Gatos, Calif. In addition to cancer care, key medical specialties include behavioral health, heart and vascular, men's health, neuroscience, orthopedic and spine, senior health, urology, and the first Women's Hospital in Northern California. The hospital is recognized as a national leader in the use of health information technology and wireless communications, and has been awarded the Gold Seal of Approval from The Joint Commission as a Primary Stroke Center, as well as back-to-back ANCC Magnet Recognitions for Nursing Care.\n About Cyrcadia Health\n Cyrcadia Health, founded as First Warning Systems in 2008, is based in Reno, Nev. The company's product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the product. Cyrcadia Health technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc. (OTC PINK: LLBO). The company is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets, with FDA applications following for the US market. Visit Cyrcadia Health at www.cyrcadiahealth.com.\n About Lifeline Biotechnologies, Inc...